Key Developments: Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

10.93EUR
8:13am EST
Price Change (% chg)

€0.12 (+1.11%)
Prev Close
€10.81
Open
€11.00
Day's High
€11.00
Day's Low
€10.80
Volume
2,354
Avg. Vol
4,737
52-wk High
€12.10
52-wk Low
€9.40

Search Stocks

Latest Key Developments (Source: Significant Developments)

Vexim joins new EnterNext PEA-PME 150 index
Monday, 17 Nov 2014 02:00am EST 

Vexim SA:Joins new EnterNext PEA-PME 150 index.  Full Article

Vexim to commence U.S. sales and marketing operations with appointment of regional sales director
Wednesday, 12 Nov 2014 02:00am EST 

Vexim SA:Names Christopher M. Staubly to newly created post of Director of U.S. National Sales.Appointment is to commence company U.S. sales and marketing operations.  Full Article

Vexim SA to initiate clinical study
Monday, 13 Oct 2014 02:00am EDT 

Vexim SA:Will initiate a new clinical study that will support its planned application for 510(k) regulatory clearance to market SpineJack in the U.S.The company expects to complete the study in 2 years' time in support of a 510(k) submission in 2017.  Full Article

Vexim announces positive preliminary results of Spinejack and Medtronic balloon comparison
Tuesday, 30 Sep 2014 12:00pm EDT 

Vexim SA:Announces positive preliminary results at six months of study comparing safety and performances of Spinejack to Medtronic balloon.Results concern treatment of vertebral compression fractures in patients with osteoporosis.  Full Article

Vexim announces 12-month results of study of performance of SpineJack in treating acute fresh traumatic vertebral compression fractures
Monday, 19 May 2014 11:45am EDT 

Vexim SA:Says 12-month results of an international study on 103 patients confirm performance of SpineJack in treating acute fresh traumatic vertebral compression fractures.Prospective observational study was conducted consecutively in 14 clinical sites across France, Germany, Switzerland, Spain, Italy and Austria, and recruited patients with high rate of complex fractures (59 pct).Results revealed statistically advantages of SpineJack in terms of patients’ pain, function and quality of life over 12 months.Vertebral pain was assessed using Visual Analog Scale (VAS), and showed average decrease of 82 pct at 12 months (79 pct at post op).Decrease in pain effected by SpineJack also allowed reduction in analgesic consumption.12 months after the operation, 98.7 pct of patients were using mild analgesics or no medication at all.Functional capacity was measured using the Oswestry Disability Index (ODI).Results showed improvement of 86 pct in ODI scores at 12 months, following improvement of 81 pct at 3 months.Reported rate of adjacent fractures at 12 months was 2.9 pct.99 pct of surgeons involved in the study assessed SpineJack’s technical performance and safety as very good or good.No implant-related complication was reported.  Full Article

Vexim says SpineJack’s CE Mark expanded to all types of vertebral compression fractures
Tuesday, 8 Apr 2014 11:45am EDT 

Vexim SA:Says it has obtained approval in Europe to extend SpineJack system's indications to all types of vertebral compression fractures.  Full Article

Vexim SA announces results of study into use of Spinejack for vertebral compression factors
Monday, 10 Mar 2014 01:00pm EDT 

Vexim SA:Announces that results of long term retrospective study of 178 patients confirm effectiveness of SpineJack for treating vertebral compression fractures.Vertebral pain was assessed using Visual Analog Scale (VAS) and showed decrease of 75 pct at end of observation period.Functional capacity was measured using Oswestry Disability Index (ODI) and showed improvement of 92 pct at end of evaluation period.Low rate of adjacent vertebral fractures (2.2 pct) was observed.  Full Article

Vexim SA's capital increase oversubscribed up to 11.8 mln euros
Wednesday, 22 Jan 2014 01:24pm EST 

Vexim SA:Says due to the full exercise of the increase option in the company's capital increase, the initial amount of 10 million euros was finally increased to 11.8 million euros, including issue premium.Says it reflects the issuance of 1,242,000 additional new shares.Says that, in accordance with its subscription commitment, Bpifrance Participations has subscribed to the offering for an amount of 5 million euros and becomes a shareholder of the company with 8.9 percent of the share capital.  Full Article

Vexim SA launches 10 million euro capital increase
Thursday, 16 Jan 2014 01:00am EST 

Vexim SA:Announces the launch of a capital increase without preferential subscription rights nor priority subscription period, by issuance of 1,080,000 new shares.Says it aims to raise a gross amount of about 10 million euros.Says the amount of the capital increase may be increased up to a maximum of about 11.5 million euros (1,242,000 shares) in the event of the exercise in full by the Company of its option to increase the issue.Says Bpifrance Participations has committed, subject to conditions, to subscribe to the capital increase for a maximum of 50% of the issued amount and in the limit of 5 million euros.  Full Article

Vexim SA announces launch of Interface
Monday, 9 Dec 2013 11:45am EST 

Vexim SA:Says it is launching Interface, a new biomaterial for bone fixation.Says Interface is a biological alternative to existing orthopedic cements for treating traumatic vertebral fractures.  Full Article

No consensus analysis data available.
Search Stocks